Ernest Asamoah, MD
Endocrinology, Diabetes & Metabolism · Indianapolis, INNPI 1427079672
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $778,020 of the $959,331 with a category attached, or 81.1%. 60 manufacturers reported payments, led by Novo Nordisk at 37.7% of the total. Among endocrinology, diabetes & metabolism clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,355 payments — averaging $407.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$362K
- Lilly USA, LLC$130K
- AstraZeneca$115K
- Dexcom, Inc.$80K
- Amgen$70K
- Abbott$50K
- plus $152K from 54 others
What the payments were for
- Consulting fees$49,3945%
- Speaking & faculty fees$778,02081%
- Travel & lodging$83,8959%
- Food & beverage$47,3895%
- Education$6330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$153,726
- Ozempic$146,484
- FARXIGA$70,481
- MOUNJARO$68,954
- JARDIANCE$56,024
- DEXCOM G7 GSS (161)$53,068
- AFREZZA$39,443
- EVENITY$36,801
- FreeStyle Libre Pro$31,793
- DEXCOM G6 TRANSMITTER$24,686
- Tresiba$23,276
- Tirosint$19,860
- Tymlos$16,921
- TEPEZZA$15,871
- Synthroid$13,501
- Strensiq$9,799
- DEXCOM STELO GLUCOSE BIOSENSOR$8,878
- Victoza$7,473
- NEXLIZET$6,640
- NEXLETOL$6,640
How this compares
$959,331 in reported general payments places this provider in the 95th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 11 | $1,535,750 |
| MounjaroTirzepatide | 693 | $893,499 |
| OzempicSemaglutide | 380 | $697,940 |
| Tresiba Flextouch U-200Insulin Degludec | 312 | $483,272 |
| JardianceEmpagliflozin | 376 | $443,229 |
| FarxigaDapagliflozin Propanediol | 280 | $293,935 |
| TrulicityDulaglutide | 107 | $191,025 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 133 | $179,928 |
| AfrezzaInsulin Regular, Human | 19 | $108,308 |
| Humalog Kwikpen U-200Insulin Lispro | 21 | $76,323 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $75,557 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $67,621 |
| Humalog Kwikpen U-100Insulin Lispro | 130 | $57,581 |
| TradjentaLinagliptin | 41 | $49,204 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $46,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga | $115,245 | $1,829,684291 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $130,395 | $1,118,540841 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $361,601 | $752,555420 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $33,485 | $505,532431 claims |
| Mannkind CorporationAfrezza | $41,304 | $108,30819 claims |
| MerckJanuvia, Janumet Xr | $207 | $65,94971 claims |
| AbbVieSynthroid | $14,083 | $35,563354 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $534 | $18,7791,261 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $591 | $8,90311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Indianapolis
- Hisham AllababidiIndianapolis$195K
- Michael EconsIndianapolis$74K
- Carmella Evans-MolinaIndianapolis$55K
- Manuel Bello SeguraIndianapolis$44K
- Moazzam HabibIndianapolis$29K
- James EdmondsonIndianapolis$10K
- James ScheidlerIndianapolis$8K
- Cary MariashIndianapolis$6K
- Jayender ChintaparthiIndianapolis$5K
- Munro PeacockIndianapolis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.